**All Interactions with Elvitegravir (Vitekta)**

| **Coadministered Drug** | **Dose of Drug** | **Dose of Elvitegravir** | **Effect on Drug Levels** | **Effect on Elvitegravir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Antacids[697](http://arv.ucsf.edu/insite?page=ar-00-02&param=259&post=4#697)  (Maalox, Mylanta, Riopan, Milk of Magnesia, others) | - | 150 mg | - | Elvitegravir AUC decreased 40-50% if given simultaneously with an antacid and a boosted protease inhibitor. Elvitegravir AUC decreased 15-20% if given simultaneously with boosted PI, but antacid was separated by 2 hours. No change in AUC if elvitegravir given simultaenously with boosted PI and antacid is separated by 4 hours. | Potentially decreased elvitegravir effectiveness if given simultaneously with boosted PI and antacid | Chelation of integrase inhibitors by divalent cations | When giving elvitegravir with a boosted PI, separate antacids by at least 2 hours. |
| Rifabutin[697](http://arv.ucsf.edu/insite?page=ar-00-02&param=259&post=4#697)  (Mycobutin)(Mycobutin) | 150 mg every other day | 300 mg plus 100 mg ritonavir | Increased rifabutin levels and increased rifabutin metabolite (25-O-desacetylrifabutin). Potential increase of 25-O-desacetylrifabutin AUC of 951% if given with elvitegravir with a ritonavir-boosted protease inhibitor | No effect | Potential for increased rifabutin toxicity | Inhibition of CYP3A4 | Use rifabutin 150mg once daily or 300 mg three times weekly if co-administering with elvitegravir and a ritonavir-boosted PI. |
| "-" indicates that there are no data available | | | | | | | |

|  |  |
| --- | --- |
| 697: | Vitekta [package insert]. Gilead Sciences; Foster City, CA. July 2015 |